Skip to main content
GutCited

연구 프로세스

477 동료 심사 연구의 그림

전체 생강 아연 이눌린 커큐민 락타아제 베르베린 차전자피 비피도박테리움 롱검 비피도박테리움 락티스 비피도박테리움 비피덤 사카로마이세스 보울라디 락토바실루스 가세리 락토바실루스 플란타룸 락토바실루스 애시도필루스 부티레이트(나트륨/칼슘 부티레이트) 페퍼민트 오일 바실루스 코아굴란스 췌장효소(판크렐리파아제) 알로에 베라(내엽 젤) 알파-갈락토시다아제 소 초유 오메가-3 지방산(EPA/DHA) 비타민 A 비타민 D 프럭토올리고당(FOS) 갈락토올리고당(GOS) L-글루타민 중쇄중성지방(MCT 오일) N-아세틸시스테인(NAC)
All Types Chart Diagram Photograph Flowchart Forest Plot Micrograph Other
Figure 2. Transmission electron microscopic, TEM, images of mucopenetrative liposomes (A). MP3, cationic liposomes with Pluronic F-127 (B). MP1, neutral liposomes with Pluronic F-127. For formulations’ composition, refer to Table 1.
Figure 3

Figure 2. Transmission electron microscopic, TEM, images of mucopenetrative liposomes (A). MP3, cationic liposomes with Pluronic F-127 (B). MP1, neutral liposomes with Pluronic F-127. For formulations’ composition, refer to Table …

Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in …

Figure 3. Diffusion of mucopenetrative liposomal particles from MP1 to MP6 through 1 mm thick sigma mucin type I in a silicon tube maintained at pH 6.0 at 37 ◦C at 1, 2, and 3 hours’ time (n = 3, mean ± SD shown). Abbreviations: MP1 (neutral with Pluronic
Figure 4

Figure 3. Diffusion of mucopenetrative liposomal particles from MP1 to MP6 through 1 mm thick sigma mucin type I in a silicon tube maintained at pH 6.0 at 37 ◦C …

Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in …

Figure 5
Figure 5

Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in …

Figure 7
Figure 7

Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in …

Figure 8
Figure 8

Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in …

Figure 9
Figure 9

Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in …

Figure 11
Figure 11

Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in …

Figure 2
Figure 2

Fructooligosaccharides for Relieving Functional Constipation: A Systematic Review and Meta-Analysis of Randomized …

Figure 3
Figure 3

Fructooligosaccharides for Relieving Functional Constipation: A Systematic Review and Meta-Analysis of Randomized …

Figure 2
Figure 2

Sodium butyrate regulates macrophage polarization by TGR5/β-arrestin2 in vitro.

Figure 3
Figure 3

Sodium butyrate regulates macrophage polarization by TGR5/β-arrestin2 in vitro.

Figure 4
Figure 4

Sodium butyrate regulates macrophage polarization by TGR5/β-arrestin2 in vitro.

Figure 5
Figure 5

Sodium butyrate regulates macrophage polarization by TGR5/β-arrestin2 in vitro.

Figure 6
Figure 6

Sodium butyrate regulates macrophage polarization by TGR5/β-arrestin2 in vitro.

Figure 1
Figure 1

Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic …

Figure 2. NBCs with potential therapeutic roles in T2D and MASLD.
Figure 3

Figure 2. NBCs with potential therapeutic roles in T2D and MASLD.

Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic …

Figure 1. Main mechanisms of action of functional foods, herbal medicine, and other nutraceuticals in IBS. Each icon next to the medicinal products indicates which of the five main pathophysiological mechanisms of IBS the product targets.
Figure 1

Figure 1. Main mechanisms of action of functional foods, herbal medicine, and other nutraceuticals in IBS. Each icon next to the medicinal products indicates which of the five main pathophysiological …

Functional Foods and Nutraceuticals in Irritable Bowel Syndrome.

Figure 4
Figure 4

Pharmacological effects of different ginger juices on the concurrent symptoms in animal …

Figure 5
Figure 5

Pharmacological effects of different ginger juices on the concurrent symptoms in animal …

Figure 2
Figure 2

Open-label long-term treatment of add-on triheptanoin in adults with drug-resistant epilepsy.

Figure 3
Figure 3

Open-label long-term treatment of add-on triheptanoin in adults with drug-resistant epilepsy.

FIGURE 3 A, Duration on full treatment dose and B the changes in body weight are shown for all participants. B, The changes in body weight (kg) from the beginning of the study until the end of the triheptanoin treatment vs until the end of the full study
Figure 4

FIGURE 3 A, Duration on full treatment dose and B the changes in body weight are shown for all participants. B, The changes in body weight (kg) from the beginning …

Open-label long-term treatment of add-on triheptanoin in adults with drug-resistant epilepsy.

Figure 6
Figure 6

Prophylactic Effect of Bovine Colostrum on Intestinal Microbiota and Behavior in Wild-Type …

Figure 7
Figure 7

Prophylactic Effect of Bovine Colostrum on Intestinal Microbiota and Behavior in Wild-Type …

20페이지 중 18페이지